Yoshitsugu Obi, MD
Nephrology · Jackson, MSNPI 1730748443
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (48.8%), food and beverage and education — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Kyowa Kirin Co., Ltd at 48.8% of the total. Reporting peaked in 2022 at $1,272 and has fallen 77.6% since, to $285 in 2025.
Across 15 payments — averaging $136.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kyowa Kirin Co., Ltd$1K
- Novartis$162
- Amgen$161
- Ardelyx, Inc.$125
- Sanofi$124
- Mallinckrodt Hospital Products Inc.$122
- plus $356 from 6 others
What the payments were for
- Speaking & faculty fees$1,00049%
- Food & beverage$91244%
- Education$1397%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kyowa Kirin Co., Ltd | 1 | $1,000 |
| Novartis | 2 | $162 |
| Amgen(2 entities) | 2 | $161 |
| Ardelyx, Inc. | 1 | $125 |
| Sanofi | 1 | $124 |
| Mallinckrodt Hospital Products Inc. | 1 | $122 |
| AstraZeneca | 2 | $118 |
| Calliditas Therapeutics US Inc. | 1 | $110 |
| Baxter Healthcare | 1 | $45 |
| GSK | 1 | $39 |
| Genentech, Inc. | 1 | $25 |
| Nxstage Medical, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XPHOZAH 30 MG$125
- FABRAZYME$124
- TERLIVAZ$122
- TARPEYO$110
How this compares
$2,051 in reported general payments places this provider in the 55th percentile of 105 nephrology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XphozahTenapanor Hcl | 25 | $70,256 |
| Sevelamer Carbonate | 12 | $4,335 |
| Nifedipine ErNifedipine | 14 | $351 |
| Torsemide | 12 | $327 |
| Nystatin | 17 | $256 |
| Losartan Potassium | 38 | $171 |
| Amlodipine Besylate | 16 | $99 |
| Carvedilol | 14 | $96 |
| Atorvastatin Calcium | 12 | $71 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Jackson
- Ramzi VareldzisJackson$3K
- Murphy MartinJackson$3K
- James OnyirimbaJackson$2K
- Pradeep Kumar VaitlaJackson$2K
- Carla MonicoJackson$2K
- Uma Mahesh AvulaJackson$1K
- Mohit AhujaFlowood$427K
- Padam HirachanNatchez$29K
- Brian RifkinHattiesburg$23K
- Otis GowdyMeridian$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.